Arama yapmak istediğiniz kelime yazın ve enter’a basın.
A-Z İçerik, Sayfa Rehberi
ABC-ÇDEGHKMPTU-ÜY
Yayınlar
Prof. Dr. Sinem Ezgi Gülmez

  • Kaya M, Duru M, Gulmez SE. Toward Kidney-Specific Causality Assessment Tool. Clin Ther. 2022 Jul;44(7):e59-e75. doi: 10.1016/j.clinthera.2022.05.008. Epub 2022 Jun 18.
  • Gulmez SE, Aydin V, Akici A. Footprints of Clinical Pharmacology in Turkey: Past, Present, and Future. Clin Ther. 2020 Feb;42(2):351-362. doi: 10.1016/j.clinthera.2019.12.014. Epub 2020 Jan 16. PMID: 31955969.
  • Duru M, Meydan O, Kaya M, Gulmez SE. Need for Causality Assessment Tool for Drug-induced Acute Kidney Injury. Clin Ther. 2019 Sep;41(9):1894-1897. doi: 10.1016/j.clinthera.2019.07.013. Epub 2019 Aug 9. PMID: 31405528.

Prof. Dr. Hakan S. Orer

  • Orer HS. IUBMB/PSBMB 2019 Conference/Plenary: Mentoring in postgraduate training and the role of Organization for PhD Education in Health Sciences in European System. Biochem Mol Biol Educ. 2020 Nov;48(6):592-595. doi: 10.1002/bmb.21345. Epub 2020 Mar 23. PMID: 32203636.
  • Seitz BM, Orer HS, Krieger-Burke T, Darios ES, Thompson JM, Fink GD, Watts SW. 5-HT causes splanchnic venodilation. Am J Physiol Heart Circ Physiol. 2017 Sep 1;313(3):H676-H686. doi: 10.1152/ajpheart.00165.2017. Epub 2017 Jun 16. PMID: 28626072; PMCID: PMC5625177.
  • Wehrwein EA, Orer HS, Barman SM. Overview of the Anatomy, Physiology, and Pharmacology of the Autonomic Nervous System. Compr Physiol. 2016 Jun 13;6(3):1239-78. doi: 10.1002/cphy.c150037. PMID: 27347892.

Dr. Öğr. Üyesi Gülnihal Özcan

  • Ozcan G. The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. Front Cell Dev Biol. 2023 Feb 8;11:1082057. doi:10.3389/fcell.2023.1082057. PMID: 36846589; PMCID: PMC9945545.
  • Özcan G. SCUBE2 as a Marker of Resistance to Taxane-based Neoadjuvant Chemotherapy and a Potential Therapeutic Target in Breast Cancer. Eur J Breast Health. 2023 Jan 1;19(1):45-54. doi: 10.4274/ejbh.galenos.2022.2022-8-2. eCollection 2023 Jan. PMID: 36605472 Free PMC article.
  • Ucaryilmaz Metin C, Ozcan G. Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer. BMC Cancer. 2022 Jun 23;22(1):692. doi: 10.1186/s12885-022-09736-5. PMID: 35739492 Free PMC article.
  • Ucaryilmaz Metin C, Ozcan G. The HIF-1α as a Potent Inducer of the Hallmarks in Gastric Cancer. Cancers (Basel). 2022 May 30;14(11):2711. doi: 10.3390/cancers14112711.
  • Almammadov T, Atakan G, Leylek O, Ozcan G, Gunbas G, Kolemen S. Resorufin Enters the Photodynamic Therapy Arena: A Monoamine Oxidase Activatable Agent for Selective Cytotoxicity. ACS Med Chem Lett. 2020 Nov 23;11(12):2491-2496. doi: 10.1021/acsmedchemlett.0c00484. PMID: 33335672; PMCID: PMC7734820.
  • Ozcan G. Clinical Development of HIF-1α inhibitors for Cancer Therapy. Medical Diagnosis and Treatment Methods in Basic Medical Sciences, 2020 Dec; 16-38. Livre de Lyon, ISBN 978-2-38236-061-3. Ed. Sıddık Keskin.

Doç. Dr. Nathan Lack

  • Morova T, Ding Y, Huang CF, Sar F, Schwarz T, Giambartolomei C, Baca SC, Grishin D, Hach F, Gusev A, Freedman ML, Pasaniuc B, Lack NA. Optimized high-throughput screening of non-coding variants identified from genome-wide association studies. Nucleic Acids Res. 2022;gkac1198.
  • Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, Wells C, Foo J, Khan N, Morin H, Saxena N, Kung SHY, Sun B, Parra Nuñez AK, Sanchez C, Chan N, Ung L, Altıntaş UB, Bui JM, Wang Y, Fazli L, Oo HZ, Rennie PS, Lack NA, Cherkasov A, Gleave ME, Gsponer J, Lallous N. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression. Nucleic Acids Res. 2023;51(1):99-116.
  • Kneppers J, Severson TM, Siefert JC, Schol P, Joosten SEP, Yu IPL, Huang CF, Morova T, Altıntaş UB, Giambartolomei C, Seo JH, Baca SC, Carneiro I, Emberly E, Pasaniuc B, Jerónimo C, Henrique R, Freedman ML, Wessels LFA, Lack NA, Bergman AM, Zwart W. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential. Nat Commun. 2022;13(1):7367.
  • Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, Ding Y, Schwarz T, Huang CF, Anderson J, Fay AP, Kalita C, Groha S, Pomerantz MM, Wang V, Linder S, Sweeney CJ, Zwart W, Lack NA, Pasaniuc B, Takeda DY, Gusev A, Freedman ML. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nat Genet. 2022;54(9):1364-1375
  • Yedier-Bayram O, Gokbayrak B, Kayabolen A, Aksu AC, Cavga AD, Cingöz A, Kala EY, Karabiyik G, Günsay R, Esin B, Morova T, Uyulur F, Syed H, Philpott M, Cribbs AP, Kung SHY, Lack NA, Onder TT, Bagci-Onder T. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities. Cell Death Dis. 2022;13(8):710.
  • Kayabolen A, Akcan U, Özturan D, Ulbegi-Polat H, Sahin GN, Pinarbasi-Degirmenci N, Bayraktar C, Soyler G, Sarayloo E, Nurtop E, Ozer B, Guney-Esken G, Barlas T, Yildirim IS, Dogan O, Karahuseyinoglu S, Lack NA, Kaya M, Albayrak C, Can F, Solaroglu I, Bagci-Onder T. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo. Adv Sci (Weinh). 2022;9(27):e2201294
  • Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Schönlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME; SU2C/PCF West Coast Prostate Cancer Dream Team; Quigley DA, Feng FY, Chi KN, Wyatt AW. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022 ;608(7921):199-208.
  • Linder S, Hoogstraat M, Stelloo S, Eickhoff N, Schuurman K, de Barros H, Alkemade M, Bekers EM, Severson TM, Sanders J, Huang CF, Morova T, Altintas UB, Hoekman L, Kim Y, Baca SC, Sjöström M, Zaalberg A, Hintzen DC, de Jong J, Kluin RJC, de Rink I, Giambartolomei C, Seo JH, Pasaniuc B, Altelaar M, Medema RH, Feng FY, Zoubeidi A, Freedman ML, Wessels LFA, Butler LM, Lack NA, van der Poel H, Bergman AM, Zwart W. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence. Cancer Discov. 2022 ;12(9):2074-2097.
  • Zhang Y, Donaher JL, Das S, Li X, Reinhardt F, Krall JA, Lambert AW, Thiru P, Keys HR, Khan M, Hofree M, Wilson MM, Yedier-Bayram O, Lack NA, Onder TT, Bagci-Onder T, Tyler M, Tirosh I, Regev A, Lees JA, Weinberg RA. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat Cell Biol. 2022;24(4):554-564.
  • Mendes AA, Lu J, Kaur HB, Zheng SL, Xu J, Hicks J, Weiner AB, Schaeffer EM, Ross AE, Balk SP, Taplin ME, Lack NA, Tekoglu E, Maynard JP, De Marzo AM, Antonarakis ES, Sfanos KS, Joshu CE, Shenderov E, Lotan TL. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. Cancer. 2022;128(12):2269-2280.